Momenta Pharmaceuticals (NASDAQ:MNTA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

MNTA has been the topic of several other research reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Cowen set a $15.00 target price on Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. Momenta Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $15.30.

Momenta Pharmaceuticals (NASDAQ MNTA) opened at $16.30 on Tuesday. Momenta Pharmaceuticals has a 52-week low of $11.85 and a 52-week high of $19.55. The stock has a market capitalization of $1,250.00, a P/E ratio of -20.38 and a beta of 1.80.

In related news, CEO Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total value of $54,948.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Elizabeth Stoner sold 16,264 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $18.00, for a total value of $292,752.00. Following the completion of the sale, the director now owns 32,440 shares in the company, valued at approximately $583,920. The disclosure for this sale can be found here. Insiders have sold a total of 77,354 shares of company stock worth $1,170,153 in the last quarter. 4.40% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtus Fund Advisers LLC acquired a new stake in shares of Momenta Pharmaceuticals in the 4th quarter worth approximately $1,012,000. BlackRock Inc. grew its holdings in shares of Momenta Pharmaceuticals by 0.8% in the 4th quarter. BlackRock Inc. now owns 10,473,316 shares of the biotechnology company’s stock worth $146,105,000 after acquiring an additional 82,691 shares during the period. Rhumbline Advisers grew its holdings in shares of Momenta Pharmaceuticals by 16.5% in the 4th quarter. Rhumbline Advisers now owns 175,202 shares of the biotechnology company’s stock worth $2,444,000 after acquiring an additional 24,862 shares during the period. Arizona State Retirement System grew its holdings in shares of Momenta Pharmaceuticals by 224.8% in the 4th quarter. Arizona State Retirement System now owns 128,388 shares of the biotechnology company’s stock worth $1,791,000 after acquiring an additional 88,854 shares during the period. Finally, Pinebridge Investments L.P. grew its holdings in shares of Momenta Pharmaceuticals by 351.6% in the 4th quarter. Pinebridge Investments L.P. now owns 42,716 shares of the biotechnology company’s stock worth $596,000 after acquiring an additional 33,257 shares during the period. Institutional investors and hedge funds own 93.01% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Momenta Pharmaceuticals (MNTA) Upgraded to Buy by BidaskClub” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/momenta-pharmaceuticals-mnta-upgraded-to-buy-by-bidaskclub/1862253.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.